These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15696902)

  • 1. [Lipid-lowering therapy in chronic kidney disease].
    Fernández-Vega F
    Nefrologia; 2004; 24 Suppl(6):113-26, 187-235. PubMed ID: 15696902
    [No Abstract]   [Full Text] [Related]  

  • 2. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
    Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
    Am J Kidney Dis; 2003 Apr; 41(4 Suppl 3):I-IV, S1-91. PubMed ID: 12671933
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid lowering therapy for adults with diabetes.
    Jackowski L; Crockett J; Rowett D
    Aust Fam Physician; 2008; 37(1-2):39-41. PubMed ID: 18239751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of hyperlipidemia in human renal disease.
    D'Amico GD; Gentile MG
    Miner Electrolyte Metab; 1993; 19(3):196-204. PubMed ID: 8232107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment of lipid disorders.
    Knopp RH
    N Engl J Med; 1999 Aug; 341(7):498-511. PubMed ID: 10441607
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetic maculopathy and lipid-lowering therapy.
    Misra A; Vikram NK; Kumar A
    Eye (Lond); 2004 Jan; 18(1):107-8. PubMed ID: 14707990
    [No Abstract]   [Full Text] [Related]  

  • 11. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
    Krane V; Wanner C
    Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
    Kiberd BA
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):354-5. PubMed ID: 16932460
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperlipidemia treatment in children: the younger, the better.
    Gauer R
    Am Fam Physician; 2010 Sep; 82(5):460. PubMed ID: 20822078
    [No Abstract]   [Full Text] [Related]  

  • 15. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
    Genest J; Frohlich J; Fodor G; McPherson R;
    CMAJ; 2003 Oct; 169(9):921-4. PubMed ID: 14581310
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypertriglyceridemia and cardiovascular disease management.
    Codario RA
    J Am Acad Nurse Pract; 2007; 19(12 Suppl 2):7-10, 13-4. PubMed ID: 18510282
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipid abnormalities and cardiovascular risk in renal disease.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2008 Jun; 19(6):1065-70. PubMed ID: 18369085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein metabolism and lipid management in chronic kidney disease.
    Kwan BC; Kronenberg F; Beddhu S; Cheung AK
    J Am Soc Nephrol; 2007 Apr; 18(4):1246-61. PubMed ID: 17360943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.